Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Pant Discusses the Current Treatment Landscape of CRC

November 22nd 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the current treatment landscape of colorectal cancer.

Emerging Developments in NETs, Liver Cancer

November 21st 2017

Scott Paulson, MD, discusses developments with NETs and liver cancer.

Dr. McCollum on Drug Sequences for Patients With CRC

November 18th 2017

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Dr. Becerra on Emerging Treatments in Pancreatic Cancer

November 17th 2017

Carlos Becerra, MD, physician, Texas Oncology, discusses emerging treatments for patients with pancreatic cancer.

Dr. McCollum on Treatment in the First-Line Setting for CRC

November 17th 2017

A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

Lower-Dose Sorafenib Linked to Reduced Discontinuation Rate in HCC

November 16th 2017

Results from a retrospective, multi-institutional study showed that lowering the dose of sorafenib (Nexavar) for patients with HCC reduced pill burden and treatment costs, while showing a trend toward improved treatment completion.

Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors

November 16th 2017

Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).

Dr. Bendell on the Future of Regorafenib for Patients With CRC

November 15th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Pembrolizumab Effective in Esophageal Carcinoma

November 14th 2017

Pembrolizumab (Keytruda) induced an overall response rate of 30% in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017